Pyroptosis

Overview

Pyroptosis (Greek: "fiery death") was initially described as a caspase-1-dependent cell death triggered by intracellular bacteria. For years it was thought of as an unusual, bacteria-specific program. That view changed dramatically in 2015, when gasdermin D (GSDMD) was identified as the actual pore-forming executioner — a protein cleaved by inflammatory caspases to release its N-terminal fragment, which oligomerizes in the plasma membrane and punches holes that kill the cell and flood the extracellular space with inflammatory cargo. Today the gasdermin family (GSDMA-E and pejvakin) is recognized as a general class of executioners whose activation can be driven by many proteases, placing pyroptosis at the center of innate immunity, inflammation, and tumor immunology.

Morphologically, pyroptotic cells swell, form membrane blebs, and eventually rupture — distinct from apoptotic chromatin condensation and membrane preservation. They release mature IL-1β, IL-18, HMGB1, lactate dehydrogenase, and cellular contents that drive inflammation.

How It Works

The Inflammasome

Classical pyroptosis is launched by cytosolic supramolecular platforms called inflammasomes. The best-known is NLRP3, but NLRC4, AIM2, NLRP1, and pyrin also form inflammasomes with their own triggers.

Inflammasome assembly typically requires two signals:

• Priming — pathogen-associated molecular patterns (Toll-like receptor agonists, TNF, IL-1) engage NF-κB to upregulate NLRP3, pro-IL-1β, and pro-IL-18.
• Activation — a second signal (ATP via P2X7 from purinergic signaling, pore-forming toxins, particulates, ion fluxes, mitochondrial damage, DNA in the cytosol) triggers assembly.

Assembled inflammasomes recruit ASC and activate caspase-1, which cleaves GSDMD, pro-IL-1β, and pro-IL-18 simultaneously. The GSDMD N-terminal fragment oligomerizes into ~20 nm pores in the plasma membrane, allowing IL-1β/IL-18 release and eventually driving cell lysis.

Non-Canonical and Alternative Routes

• Non-canonical inflammasome: caspase-11 (caspase-4/5 in humans) binds intracellular LPS directly and cleaves GSDMD, bypassing upstream sensors.
• Caspase-8 can cleave GSDMD under certain apoptotic stimuli, blurring the line with apoptosis.
• Granzyme-driven pyroptosis: natural killer and CD8 T cells deliver granzyme A, which cleaves GSDMB in target cells — a key mechanism in anti-tumor immunity.
• GSDME (DFNA5) is cleaved by caspase-3, converting what would otherwise be apoptosis into secondary pyroptosis when GSDME is highly expressed.

Termination and Pore Regulation

Membrane repair machinery (ESCRT-III) attempts to heal GSDMD pores, buying cells time. Failure tips toward full pyroptotic lysis. Ninjurin-1 executes terminal plasma membrane rupture.

Biological Roles

Host Defense

Pyroptosis is a potent anti-microbial mechanism: it eliminates the intracellular replicative niche of pathogens such as Salmonella, Shigella, Legionella, Listeria, and certain viruses, and recruits neutrophils through released alarmins. It complements other innate immune pathways such as the complement system.

Sterile Inflammation and Disease

Inappropriate or chronic pyroptosis contributes to many diseases:

• Autoinflammatory syndromes (CAPS, FMF) driven by NLRP3 and pyrin gain-of-function.
• Metabolic disease — NLRP3 activation by fatty acids, cholesterol crystals, and islet amyloid polypeptide contributes to atherosclerosis, type 2 diabetes, and non-alcoholic steatohepatitis.
• Neurodegeneration — microglial NLRP3 activation in Alzheimer's, Parkinson's, and MS.
• Sepsis and ARDS — exaggerated gasdermin activation drives tissue damage and coagulopathy.
• Cancer — pyroptosis can be pro-tumorigenic (chronic inflammation) or anti-tumorigenic (immunogenic cell death promoting CD8 T cell responses).

Relevance to Peptides

• Antimicrobial peptides (AMPs) and their host-defense activities intersect with pyroptosis: AMPs can enter infected cells and contribute to pathogen clearance, while some pathogens release peptide-like inhibitors of gasdermins.
• Peptide modulators of inflammasomes: peptide inhibitors of NLRP3 (e.g., derivatives of the pyrin B30.2 domain) and ASC are research tools and candidate drugs.
• Peptide delivery of gasdermin fragments is an emerging oncology concept — forcing pyroptosis in tumors to turn immunologically "cold" tumors "hot."
• Crosstalk with IL-1 and IL-18 biology: clinically used IL-1 blockers (anakinra, canakinumab, rilonacept) act downstream of pyroptosis-derived cytokines.

Therapeutic Implications

Targeting pyroptosis is bidirectional:

• Blocking pyroptosis is valuable in autoinflammatory disease, ischemia-reperfusion injury, sepsis, and neurodegeneration. MCC950 (NLRP3 inhibitor), disulfiram and bumetanide derivatives (GSDMD inhibitors), and selective caspase-1 inhibitors are in clinical development.
• Inducing pyroptosis selectively in tumor cells is being explored, including peptide-PROTACs that activate gasdermins, oncolytic viruses that trigger inflammasomes, and combinations with immune checkpoint inhibitors.

Current Questions

How to deliver pyroptosis modulators with tissue selectivity, why some gasdermins serve non-cell-death functions (for example GSDMA and GSDMB in epithelial biology), and how pyroptosis, apoptosis, and ferroptosis integrate into a unified "regulated cell death" network are all under active investigation. The interplay between pyroptosis and autophagy, particularly in mitochondrial quality control, continues to reveal new regulatory nodes.